Ambry Genetics to Develop Custom Assays Targeted to Patients with Hereditary Ovarian Cancer

March 25, 2019

FOR IMMEDIATE RELEASE

Ambry Genetics
1 Enterprise
Aliso Viejo, CA 92656

Investigating new testing options to identify patients for clinical trials

Aliso Viejo, CA (March 13, 2019); Ambry Genetics, a Konica Minolta Company (Ambry), and leading provider of clinical and research genetic testing, today announced a new laboratory services agreement with Clovis Oncology Inc., a biopharmaceutical company which shares Ambry’s commitment to advancing precision medicine for cancer.  Through this laboratory services agreement, Ambry Genetics and Clovis Oncology seek to identify clinical trial patients who may benefit from Rubraca®, a therapy currently approved in the U.S. and Europe in multiple advanced ovarian cancer settings.

Approximately 10 to 15% of ovarian cancer diagnoses are based on hereditary mutations of BRCA, meaning they are directly linked to mutations in the BRCA1 or BRCA2 genes passed on from a parent. Ambry’s genetic tests can identify mutations in these two genes, as well as related genes involved in the DNA repair pathway, thus enabling identification of potential risk, earlier diagnosis and more precise treatment. 

"We are very excited to be working with the Clovis team, which is aligned with our precision medicine initiatives,” said Brigette Tippin Davis, Ph.D., FACMG, Senior Vice President of Research & Development of Ambry Genetics, Inc. “Our mission is to help identify patients eligible for optimal therapies to improve outcomes and enhance quality of life.”

Clovis chose to perform retrospective BRCA testing with Ambry Genetics, a high-quality genetics lab positioned to become a key player in the precision medicine space.

Press Contact:
Jackie Copp
Jackie@PitchPublicRelations.com
480.606.8180

About Ambry Genetics ®

Ambry Genetics, a Konica Minolta Company, excels at translating scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. Our unparalleled track record of discoveries over 20 years, and growing database that continues to expand in collaboration with academic, corporate and pharmaceutical partners, means we are first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions. We care about what happens to real people, their families, and the people they love, and remain dedicated to providing them and their clinicians with deeper knowledge and fresh insights, so together they can make informed, potentially life-altering healthcare decisions. For more information, please visit ambrygen.com.

Press Contact:
Olivia Duarte
press@ambrygen.com
(949) 457-4335

Search Results

Start your search...